Figure 3

Silencing of IGF2BP3 inhibits the proliferation of HCC cells. (A,B) Gene set enrichment analysis was used to evaluate the enrichment scores of the indicated gene set37 in the high- and low-IGF2BP3-expression groups in TCGA-LIHC and GSE14520 cohorts. NES, normalized enrichment score; FDR, false discovery rate. (C) qRT-PCR was used to assess IGF2BP3 expression in hepatic tumor cells. (D) qRT-PCR validated the siRNA-mediated knockdown of IGF2BP3 in Hep3B and HepG2 cells. (E) CCK-8 assay revealed that siRNA-mediated downregulation of IGF2BP3 significantly decreased the growth rate of Hep3B (top) and HepG2 (bottom) cells. (F, G) Representative micrographs and quantification of EdU incorporation in the indicated cells. Significant differences were estimated via two-way ANOVA (E) or one-way ANOVA with Turkey post hoc tests (D,G).